Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.83
NYSE:BAX's Cash to Debt is ranked lower than
60% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NYSE:BAX: 0.83 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.31 Max: 1.13
Current: 0.83
0.09
1.13
Equity to Asset 0.53
NYSE:BAX's Equity to Asset is ranked lower than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NYSE:BAX: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.34 Max: 0.53
Current: 0.53
0.22
0.53
Interest Coverage 4.24
NYSE:BAX's Interest Coverage is ranked lower than
86% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NYSE:BAX: 4.24 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.86 Max: 32.02
Current: 4.24
3.08
32.02
F-Score: 4
Z-Score: 5.17
M-Score: -2.78
WACC vs ROIC
5.69%
4.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.23
NYSE:BAX's Operating margin (%) is ranked higher than
54% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NYSE:BAX: 5.23 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BAX' s Operating margin (%) Range Over the Past 10 Years
Min: 4.5  Med: 18.5 Max: 22.9
Current: 5.23
4.5
22.9
Net-margin (%) 47.74
NYSE:BAX's Net-margin (%) is ranked higher than
97% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NYSE:BAX: 47.74 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BAX' s Net-margin (%) Range Over the Past 10 Years
Min: 9.71  Med: 16.16 Max: 47.74
Current: 47.74
9.71
47.74
ROE (%) 56.87
NYSE:BAX's ROE (%) is ranked higher than
97% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NYSE:BAX: 56.87 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BAX' s ROE (%) Range Over the Past 10 Years
Min: 11.41  Med: 28.27 Max: 56.87
Current: 56.87
11.41
56.87
ROA (%) 22.96
NYSE:BAX's ROA (%) is ranked higher than
97% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NYSE:BAX: 22.96 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BAX' s ROA (%) Range Over the Past 10 Years
Min: 4.11  Med: 10.79 Max: 22.96
Current: 22.96
4.11
22.96
ROC (Joel Greenblatt) (%) 65.60
NYSE:BAX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NYSE:BAX: 65.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.65  Med: 37.11 Max: 65.6
Current: 65.6
5.65
65.6
Revenue Growth (3Y)(%) -10.20
NYSE:BAX's Revenue Growth (3Y)(%) is ranked lower than
79% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NYSE:BAX: -10.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 6.7 Max: 17.3
Current: -10.2
-10.2
17.3
EBITDA Growth (3Y)(%) -28.30
NYSE:BAX's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NYSE:BAX: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: 6.6 Max: 33.1
Current: -28.3
-28.3
33.1
EPS Growth (3Y)(%) -44.00
NYSE:BAX's EPS Growth (3Y)(%) is ranked lower than
93% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NYSE:BAX: -44.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 61.5
Current: -44
-44
61.5
» NYSE:BAX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BAX Guru Trades in Q3 2015

George Soros 509,700 sh (New)
Louis Moore Bacon 210,000 sh (New)
Jim Simons 728,232 sh (New)
Tom Gayner 10,000 sh (New)
Jana Partners 12,580,576 sh (New)
Daniel Loeb 53,850,000 sh (+1263.29%)
Vanguard Health Care Fund 7,195,480 sh (+269.91%)
Keeley Asset Management Corp 82,100 sh (+33.32%)
Charles Brandes 311,631 sh (+28.84%)
First Eagle Investment 1,056,700 sh (+25.40%)
Manning & Napier Advisors, Inc 203,293 sh (+14.22%)
Murray Stahl 13,972 sh (+7.30%)
John Rogers 66,331 sh (+7.07%)
John Hussman 2,700 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Diamond Hill Capital Sold Out
Pioneer Investments Sold Out
Dodge & Cox Sold Out
Ken Fisher Sold Out
Steven Cohen Sold Out
David Dreman Sold Out
Signature Select Canadian Fund Sold Out
Jeff Auxier 24,631 sh (-0.40%)
Mairs and Power 2,298,348 sh (-1.50%)
Tweedy Browne 2,498,141 sh (-1.80%)
Richard Pzena 4,863,446 sh (-3.32%)
Mario Gabelli 157,850 sh (-14.19%)
John Buckingham 87,389 sh (-16.22%)
Paul Tudor Jones 79,931 sh (-24.11%)
Jeremy Grantham 55,046 sh (-70.28%)
» More
Q4 2015

BAX Guru Trades in Q4 2015

David Einhorn 503,500 sh (New)
Steven Cohen 888,700 sh (New)
Lee Ainslie 30,140 sh (New)
Louis Moore Bacon 620,000 sh (+195.24%)
Tom Gayner 22,000 sh (+120.00%)
Vanguard Health Care Fund 9,558,280 sh (+32.84%)
Charles Brandes 315,373 sh (+1.20%)
Murray Stahl 14,022 sh (+0.36%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Daniel Loeb 53,850,000 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones 79,893 sh (-0.05%)
Tweedy Browne 2,495,682 sh (-0.10%)
Mario Gabelli 156,900 sh (-0.60%)
John Buckingham 85,849 sh (-1.76%)
Mairs and Power 2,252,752 sh (-1.98%)
Richard Pzena 4,736,982 sh (-2.60%)
George Soros 495,000 sh (-2.88%)
John Rogers 63,595 sh (-4.12%)
Jeremy Grantham 52,246 sh (-5.09%)
Jeff Auxier 20,831 sh (-15.43%)
Manning & Napier Advisors, Inc 160,214 sh (-21.19%)
First Eagle Investment 808,879 sh (-23.45%)
Jim Simons 492,132 sh (-32.42%)
Keeley Asset Management Corp 50,550 sh (-38.43%)
Jana Partners 5,709,178 sh (-54.62%)
» More
Q1 2016

BAX Guru Trades in Q1 2016

Joel Greenblatt 1,695,068 sh (New)
David Einhorn 1,198,663 sh (+138.07%)
Keeley Asset Management Corp 61,500 sh (+21.66%)
Vanguard Health Care Fund 11,176,980 sh (+16.94%)
Jim Simons 517,032 sh (+5.06%)
Murray Stahl 14,122 sh (+0.71%)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 53,850,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Rogers Sold Out
Jeff Auxier Sold Out
Jana Partners Sold Out
Lee Ainslie Sold Out
Louis Moore Bacon Sold Out
Tweedy Browne 2,492,683 sh (-0.12%)
Charles Brandes 310,615 sh (-1.51%)
Mario Gabelli 153,750 sh (-2.01%)
John Buckingham 81,062 sh (-5.58%)
Manning & Napier Advisors, Inc 149,096 sh (-6.94%)
George Soros 448,200 sh (-9.45%)
Mairs and Power 2,035,912 sh (-9.63%)
Richard Pzena 4,084,406 sh (-13.78%)
Paul Tudor Jones 64,681 sh (-19.04%)
Jeremy Grantham 32,592 sh (-37.62%)
Steven Cohen 51,000 sh (-94.26%)
First Eagle Investment 1,100 sh (-99.86%)
» More
Q2 2016

BAX Guru Trades in Q2 2016

John Hussman 175,000 sh (New)
Leucadia National 700,000 sh (New)
Lee Ainslie 73,700 sh (New)
First Eagle Investment 2,129,733 sh (+193512.09%)
Jim Simons 583,200 sh (+12.80%)
Jeremy Grantham 36,465 sh (+11.88%)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
David Einhorn Sold Out
Manning & Napier Advisors, Inc Sold Out
John Buckingham Sold Out
Tweedy Browne Global Value 1,055,212 sh (-3.62%)
Daniel Loeb 51,901,767 sh (-3.62%)
Tweedy Browne 2,393,665 sh (-3.97%)
Mairs and Power 1,948,504 sh (-4.29%)
Keeley Asset Management Corp 58,610 sh (-4.70%)
Mario Gabelli 125,100 sh (-18.63%)
Richard Pzena 3,115,865 sh (-23.71%)
George Soros 284,327 sh (-36.56%)
Vanguard Health Care Fund 7,053,480 sh (-36.89%)
Joel Greenblatt 849,128 sh (-49.91%)
Paul Tudor Jones 27,459 sh (-57.55%)
Charles Brandes 75,584 sh (-75.67%)
Steven Cohen 3,600 sh (-92.94%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:ILMN, OTCPK:ESLOY, NYSE:BCR, OTCPK:CLPBY, OTCPK:TRUMY, NAS:XRAY, NYSE:BDX, NYSE:WAT, OTCPK:OCPNY, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, NYSE:STE, NAS:SIRO, OTCPK:SAUHF, NYSE:WST, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely, Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business also offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Ratios

vs
industry
vs
history
P/E(ttm) 5.45
BAX's P/E(ttm) is ranked higher than
94% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.50 vs. BAX: 5.45 )
Ranked among companies with meaningful P/E(ttm) only.
BAX' s P/E(ttm) Range Over the Past 10 Years
Min: 5.01  Med: 9.81 Max: 22.51
Current: 5.45
5.01
22.51
Forward P/E 23.92
BAX's Forward P/E is ranked lower than
52% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. BAX: 23.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 5.45
BAX's PE(NRI) is ranked higher than
93% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.80 vs. BAX: 5.45 )
Ranked among companies with meaningful PE(NRI) only.
BAX' s PE(NRI) Range Over the Past 10 Years
Min: 5.03  Med: 11 Max: 115.67
Current: 5.45
5.03
115.67
Price/Owner Earnings (ttm) 6.15
BAX's Price/Owner Earnings (ttm) is ranked higher than
92% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. BAX: 6.15 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.66  Med: 11.9 Max: 37.62
Current: 6.15
5.66
37.62
P/B 3.01
BAX's P/B is ranked higher than
53% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. BAX: 3.01 )
Ranked among companies with meaningful P/B only.
BAX' s P/B Range Over the Past 10 Years
Min: 2.05  Med: 2.63 Max: 3.34
Current: 3.01
2.05
3.34
P/S 2.58
BAX's P/S is ranked higher than
54% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BAX: 2.58 )
Ranked among companies with meaningful P/S only.
BAX' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 1.55 Max: 2.66
Current: 2.58
1.06
2.66
PFCF 56.96
BAX's PFCF is ranked lower than
82% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. BAX: 56.96 )
Ranked among companies with meaningful PFCF only.
BAX' s PFCF Range Over the Past 10 Years
Min: 6.96  Med: 11.12 Max: 266.13
Current: 56.96
6.96
266.13
POCF 20.07
BAX's POCF is ranked lower than
55% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. BAX: 20.07 )
Ranked among companies with meaningful POCF only.
BAX' s POCF Range Over the Past 10 Years
Min: 4.58  Med: 7.19 Max: 20.62
Current: 20.07
4.58
20.62
EV-to-EBIT 5.42
BAX's EV-to-EBIT is ranked higher than
93% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. BAX: 5.42 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.9 Max: 63.8
Current: 5.42
-2940.9
63.8
EV-to-EBITDA 4.69
BAX's EV-to-EBITDA is ranked higher than
93% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. BAX: 4.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 6.9 Max: 45.7
Current: 4.69
4.4
45.7
Shiller P/E 11.36
BAX's Shiller P/E is ranked higher than
92% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. BAX: 11.36 )
Ranked among companies with meaningful Shiller P/E only.
BAX' s Shiller P/E Range Over the Past 10 Years
Min: 9.68  Med: 12.87 Max: 21.84
Current: 11.36
9.68
21.84
Current Ratio 1.83
BAX's Current Ratio is ranked lower than
67% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. BAX: 1.83 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.67 Max: 2.7
Current: 1.83
1.08
2.7
Quick Ratio 1.41
BAX's Quick Ratio is ranked lower than
61% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BAX: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.13 Max: 2.02
Current: 1.41
0.74
2.02
Days Inventory 126.57
BAX's Days Inventory is ranked higher than
50% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. BAX: 126.57 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 99.71  Med: 138.8 Max: 219.03
Current: 126.57
99.71
219.03
Days Sales Outstanding 65.85
BAX's Days Sales Outstanding is ranked lower than
54% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. BAX: 65.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 65.15 Max: 112.88
Current: 65.85
58.53
112.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.04
BAX's Dividend Yield is ranked lower than
65% of the 136 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.29 vs. BAX: 1.04 )
Ranked among companies with meaningful Dividend Yield only.
BAX' s Dividend Yield Range Over the Past 10 Years
Min: 0.98  Med: 3.81 Max: 5.89
Current: 1.04
0.98
5.89
Dividend Payout 0.05
BAX's Dividend Payout is ranked higher than
98% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 0.05 )
Ranked among companies with meaningful Dividend Payout only.
BAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.02  Med: 0.43 Max: 57.5
Current: 0.05
0.02
57.5
Dividend Growth (3y) -6.80
BAX's Dividend Growth (3y) is ranked lower than
76% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. BAX: -6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.8  Med: 1.7 Max: 22.5
Current: -6.8
-6.8
22.5
Forward Dividend Yield 1.10
BAX's Forward Dividend Yield is ranked lower than
61% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BAX: 1.10 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.39
BAX's Yield on cost (5-Year) is ranked lower than
59% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. BAX: 1.39 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.31  Med: 5.07 Max: 7.85
Current: 1.39
1.31
7.85
3-Year Average Share Buyback Ratio -0.10
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. BAX: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -0.9 Max: 3.3
Current: -0.1
-2.1
3.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.58
BAX's Price/Tangible Book is ranked lower than
56% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. BAX: 5.58 )
Ranked among companies with meaningful Price/Tangible Book only.
BAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.43  Med: 5.62 Max: 15.06
Current: 5.58
3.43
15.06
Price/Projected FCF 1.09
BAX's Price/Projected FCF is ranked higher than
78% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. BAX: 1.09 )
Ranked among companies with meaningful Price/Projected FCF only.
BAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.63  Med: 1.16 Max: 2.82
Current: 1.09
0.63
2.82
Price/Median PS Value 1.67
BAX's Price/Median PS Value is ranked lower than
76% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. BAX: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
BAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.46  Med: 0.97 Max: 2.52
Current: 1.67
0.46
2.52
Price/Graham Number 1.17
BAX's Price/Graham Number is ranked higher than
84% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. BAX: 1.17 )
Ranked among companies with meaningful Price/Graham Number only.
BAX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.11  Med: 1.89 Max: 7
Current: 1.17
1.11
7
Earnings Yield (Greenblatt) (%) 18.48
BAX's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. BAX: 18.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 11.1 Max: 19.7
Current: 18.48
1.6
19.7
Forward Rate of Return (Yacktman) (%) -5.31
BAX's Forward Rate of Return (Yacktman) (%) is ranked lower than
81% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. BAX: -5.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.9  Med: 14.3 Max: 28
Current: -5.31
-11.9
28

More Statistics

Revenue (TTM) (Mil) $10,050
EPS (TTM) $ 8.68
Beta0.70
Short Percentage of Float2.77%
52-Week Range $32.18 - 49.49
Shares Outstanding (Mil)543.89

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 10,163 10,530 10,957
EPS ($) 1.68 1.94 2.29
EPS w/o NRI ($) 1.68 1.94 2.29
EPS Growth Rate
(3Y to 5Y Estimate)
17.49%
Dividends Per Share ($) 0.52 0.58 0.61
» More Articles for NYSE:BAX

Headlines

Articles On GuruFocus.com
Medical Companies Offer Good Value Opportunities Sep 16 2016 
10 Undervalued Stocks for the Defensive Investor Sep 13 2016 
Baxter Going Strong Aug 30 2016 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Aug 24 2016 
15 Best Undervalued Stocks of the Week Aug 23 2016 
10 Undervalued Stocks for the Defensive Investor Aug 22 2016 
John Hussman Buys Infosys, Southern Aug 12 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 
Daniel Loeb Portfolio Beats S&P Index for June But Stocks Down Jul 06 2016 

More From Other Websites
Baxter Ranked as One of the Most Diverse and Inclusive Workplaces Globally by Thomson Reuters Sep 26 2016
AMN Healthcare Services (AHS) Prices Senior Notes Offering Sep 26 2016
Baxter Ranked as One of the Most Diverse and Inclusive Workplaces Globally by Thomson Reuters Sep 26 2016
Masimo Foundation Co-Finds the United for Oxygen Alliance Sep 26 2016
Richard Pzena Boosted Stake in Seagate in 2nd Quarter Sep 23 2016
Becton (BDX) to Expand Syringe Capacity at Holdrege Facility Sep 23 2016
The Baxter International Foundation and Direct Relief Launch a Mobile Health Initiative Bringing... Sep 22 2016
The Baxter International Foundation and Direct Relief Launch a Mobile Health Initiative Bringing... Sep 22 2016
ETF’s with exposure to Baxter International, Inc. : September 21, 2016 Sep 21 2016
Zacks.com featured highlights: Baxter International, AO Smith, Johnson & Johnson, BWX Technologies... Sep 20 2016
Baxter (BAX) Now a Strong Buy on Solid Strategic Initiatives Sep 19 2016
5 Efficient Stocks to Ensure High Yields Sep 19 2016
Baxter Launches NUMETA G13E in Europe: Only Ready-to-Use IV Nutrition for Vulnerable Preterm... Sep 19 2016
Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : BAX-US :... Sep 19 2016
Baxter Launches NUMETA G13E in Europe: Only Ready-to-Use IV Nutrition for Vulnerable Preterm... Sep 19 2016
Barclays Bullish On Baxter International, $52 Price Target Sep 15 2016
Baxter (BAX) Stock Higher, Gets 'Overweight' Rating at Barclays Sep 15 2016
Foundation Supports Program Training the Next Generation of Community Health Advocates Sep 14 2016
Foundation Supports Program Training the Next Generation of Community Health Advocates Sep 14 2016
Baxter Recognized for 17th Consecutive Year by Dow Jones Sustainability Index (DJSI) as Responsible... Sep 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)